Innovative contracting in Europe: a Trojan Horse?By Mary Iyiola & Agnieszka Janska, with additional consultation by Smita Sealey & Barry Farrimond In a recent Share XInnovative contracting in Europe: a Trojan Horse?https://pharmaphorum.com/views-analysis-market-access/innovative-contracting-in-europe-a-trojan-horse-2/
Cost & Management of Oncology Combination RegimensOverview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there Share XCost & Management of Oncology Combination Regimenshttps://pharmaphorum.com/oncology/cost-management-of-oncology-combination-regimens/
Innovative contracting in Europe – a Trojan horse?Overview With pricing of drugs at the centre of political and social debate, the market access and pricing Share XInnovative contracting in Europe – a Trojan horse?https://pharmaphorum.com/market-access-2/innovative-contracting-in-europe-a-trojan-horse/
